



Novo Nordisk A/S ADR (NVO)

Updated May 16th, 2022 by Prakash Kolli

Key Metrics

Current Price:	\$101	5 Year CAGR Estimate:	1.9%	Market Cap:	\$237.91B
Fair Value Price:	\$74	5 Year Growth Estimate:	6.0%	Ex-Dividend Date:	08/16/22 ¹
% Fair Value:	137%	5 Year Valuation Multiple Estimate:	-6.2%	Dividend Payment Date:	08/25/22
Dividend Yield:	2.0%	5 Year Price Target	\$99	Years Of Dividend Growth:	3
Dividend Risk Score:	C	Retirement Suitability Score:	D	Rating:	Sell

Overview & Current Events

Novo Nordisk A/S ADR is a large global pharmaceutical company headquartered in Denmark. The company focuses on two core business segments: Diabetes & Obesity Care and Biopharmaceuticals. The Diabetes & Obesity Care segment manufactures insulin, related delivery systems, oral anti-diabetic products, and products to treat obesity. The Biopharmaceuticals segment manufactures products for hemophilia and other chronic diseases. Novo Nordisk derives ~55% of revenue from insulin drugs. The company's products are marketed in 170 countries but approximately 48% of net sales are from North America and the rest is international sales.² Total revenue was nearly \$20.7B in 2021.

Novo Nordisk reported excellent Q1 2022 results on April 29th, 2022. Companywide sales were up 24% in Danish kroner to 42,931M (\$5,898M) and diluted earnings per share rose 14% to 6.22 DKK (\$0.87) from 5.45 DKK (\$0.74) on a year-over-year basis. Diabetes & Obesity sales increased 27% to 36,668M DKK (\$5,145.6M) driven by increases in Tresiba and Xultophy (long-acting insulins), Ryzodeg (premix insulin), Fiasp (fast-acting insulin), Ozempic (GLP-1), Rybelsus (GLP-1), Saxenda (obesity), and Wegovy (obesity) offset by lower sales for Victoza (GLP-1), Levemir (long-acting insulin), and NovoRapid (fast-acting insulin). The Biopharmaceuticals segment sales rose 8% to 5,363M DKK (\$753M) driven by growth in hemophilia and rare disease disorder offset by declines in rare endocrine disorders.

Icodec, a long-lasting weekly insulin successfully completed Phase 3a trials. Concizumab completed phase 3 trials.

The company raised guidance to 10% - 14% sales growth and 9% - 13% operating profit growth in 2022.

Growth on a Per-Share Basis

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2027
EPS	\$1.38	\$1.73	\$1.64	\$1.98	\$2.12	\$2.48	\$2.44	\$2.47	\$2.97	\$3.04	\$3.35	\$4.48
DPS	\$0.50	\$0.62	\$0.83	\$0.73	\$1.41	\$1.14	\$1.27	\$1.23	\$1.30	\$1.47	\$2.04	\$2.86
Shares³	2,715	2,647	2,593	2,548	2,504	2,444	2,394	2,352	2,316	2,303	2,280	2,168

Novo Nordisk experienced strong earnings growth after the last recession driven by the global economic recovery, rising drug prices, and lower share count. However, earnings growth slowed due to patent expirations and competition from generics. Going forward, Novo Nordisk should generate sales growth from its portfolio of approved insulin products, Saxenda and Wegovy (obesity), Ozempic and Rybelsus (GLP-1), multiple hemophilia drugs, and Norditropin (growth disorder). According to Novo Nordisk, more than 460 million people around the world have diabetes and the numbers are expected to rise because of an increasingly overweight and aging worldwide population. We are forecasting 6% growth in earnings per share out to 2027 due to new therapy launches, higher volumes, and pricing. Novo Nordisk has been paying a growing dividend in DKK. However, currency effects can influence this consistency when translated to USD. But on average we are forecasting 7% annual growth in the dividend out to 2027.

¹ Estimated dates based in prior history. The company has not yet announced the next dividend.

² Novo Nordisk trades as an American Depositary Receipt or 'ADR' on the NYSE. The company reports quarterly earnings in Danish kroner (DKK). This report will use USD at the prevailing exchange rates.

³ Share count is in millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Novo Nordisk A/S ADR (NVO)

Updated May 16th, 2022 by Prakash Kolli

Valuation Analysis

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Now	2027
Avg. P/E	21.4	19.8	27.1	27.1	23.0	17.2	19.8	20.8	21.8	27.9	30.2	22.0
Avg. Yld.	1.7%	1.8%	1.9%	1.4%	2.9%	2.7%	2.8%	2.5%	2.0%	1.7%	2.0%	2.9%

Novo Nordisk's stock price is down slightly since our last report. We maintained our earnings estimate for 2022. Despite the lower price, the stock is still trading well above our fair value for the long haul of 22X earnings, which is the average over the past decade. Our current fair value is now \$74. Our 5-year price target is now \$99.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2027
Payout	36%	36%	51%	37%	67%	46%	52%	50%	44%	48%	61%	64%

Novo Nordisk has a strong competitive advantage with ~44% market share of the global insulin market, about 30.5% of the global diabetes market, roughly 65% of the global obesity market, about 53.6% of the GLP-1 market, and over 10% of the hemophilia market. The company has global manufacturing, distribution, and marketing scale to maintain this market share. Novo Nordisk spends on R&D to develop new drugs and expand to other indications. The company is also active in M&A to expand its pipeline in cardiovascular and renal diseases. Branded competitors exist with Sanofi and Eli Lilly for insulin. In addition, off patent insulin is available as a generic. But complex manufacturing requirements, high upfront costs, and low insulin pricing will keep most generics at bay. Novo Nordisk has recession resistant characteristics, as patients require insulin and diabetes drugs in good times or bad. The company does face patent expiration risk and pricing risk as insulin and diabetes drugs are subject to price cuts from US Medicare and Medicaid.

Final Thoughts & Recommendation

At present we are forecasting a 1.9% annualized total return through 2027 from a dividend yield of 2.0%, 6% EPS growth, and (-6.2%) P/E multiple contraction. Novo Nordisk is developing new therapies, expanding distribution, and growing market share in GLP-1 and diabetes. The R&D pipeline is productive, and several therapies are in Phase 3 trials. But the current stock price is rich. We rate this quality stock a sell at the current price.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Novo Nordisk A/S ADR (NVO)

Updated May 16th, 2022 by Prakash Kolli

Income Statement Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Revenue	13475	14881	15839	16057	16615	17002	17715	18296	19451	22404
Gross Profit	11149	12363	13242	13648	14061	14318	14924	15284	16244	18640
Gross Margin	82.7%	83.1%	83.6%	85.0%	84.6%	84.2%	84.2%	83.5%	83.5%	83.2%
SG&A Exp.	4292	4788	4773	4786	4807	4890	5277	5372	5652	6533
D&A Exp.	465	498	613	440	475	484	622	849	881	959
Operating Profit	5090	5608	6152	7356	7199	7454	7484	7869	8293	9331
Operating Margin	37.8%	37.7%	38.8%	45.8%	43.3%	43.8%	42.2%	43.0%	42.6%	41.6%
Net Profit	3701	4484	4723	5186	5637	5804	6119	5840	6456	7599
Net Margin	27.5%	30.1%	29.8%	32.3%	33.9%	34.1%	34.5%	31.9%	33.2%	33.9%
Free Cash Flow	3211	3971	4884	4743	5952	4950	5102	5331	4577	7577
Income Tax	1102	1310	1358	1283	1467	1606	1424	1440	1684	1802

Balance Sheet Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Total Assets	11639	13019	12582	13447	13871	16495	16969	18832	23953	29611
Cash & Equivalents	2048	1986	2350	2479	2658	3038	2396	2320	2109	1632
Acc. Receivable	1708	2019	2129	2268	2877	3250	3491	3735	4584	6187
Inventories	1691	1768	1854	1869	2039	2477	2503	2645	3064	2987
Goodwill & Int.	265	299	225	316	386	536	788	875	3414	6572
Total Liabilities	4438	5140	6003	6567	7433	8467	9027	10198	13487	18841
Accounts Payable	684	757	808	722	855	904	1035	953	945	1350
Long-Term Debt	89	40	118	157	33	273	79	99	1105	3428
Total Equity	7202	7879	6579	6880	6438	8028	7941	8634	10467	10770
LTD/E Ratio	0.01	0.01	0.02	0.02	0.01	0.03	0.01	0.01	0.11	0.32

Profitability & Per Share Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Return on Assets	32.3%	36.4%	36.9%	39.9%	41.3%	38.2%	36.6%	32.6%	30.2%	28.4%
Return on Equity	53.9%	59.5%	65.3%	77.1%	84.7%	80.2%	76.6%	70.5%	67.6%	71.6%
ROIC	53.0%	59.0%	64.6%	75.5%	83.5%	78.6%	75.0%	69.7%	63.6%	60.0%
Shares Out.	2,715	2,647	2,593	2,548	2,504	2,444	2,406	2,346	2,339	2,303
Revenue/Share	4.89	5.52	6.02	6.23	6.55	6.86	7.31	7.69	8.31	9.73
FCF/Share	1.16	1.47	1.86	1.84	2.35	2.00	2.10	2.24	1.96	3.29

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.